(Source: Enanta Pharmaceuticals Inc) Priority review designation shortens the regulatory review period from the standard 10 months to six months TURQUOISE-III study showed 100 percent sustained virologic response at 12 weeks post-treatment (SVR) in patients with genotype 1b (GT1b) chronic hepatitis C virus and compensated cirrhosis (Child-Pugh A) VIEKIRA PAK contains Enanta's lead protease inhibitor, paritaprevir --(BUSINESS WIRE)--Jan. 7, 2016-- , (NASDAQ:ENTA) a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that the () has accepted AbbVie's supplemental New Drug Application (sNDA)...
↧